Evidence map›Paper›PMID 35037026›Full record

ArticleBriefings in bioinformatics2022

hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy.

Yong Lu, Gang Xue, Ningbo Zheng, Kun Han, Wenzhong Yang, Rui-Sheng Wang, Lingyun Wu, Lance D Miller, Timothy Pardee, Pierre L Triozzi and 6 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yong LuDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China.
Gang XueDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China.
Ningbo ZhengDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China.
Kun HanDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China.
Wenzhong YangDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, China.
Rui-Sheng WangDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, China.
Lingyun WuAcademy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China.
Lance D MillerWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Timothy PardeeWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Pierre L TriozziWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Hui-Wen LoWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Kounosuke WatabeWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Stephen T C WongDepartments of Pathology and Genome Medicine, Weill Cornell Medicine, Houston Methodist Hospital, Houston, TX 77030, China.
Boris C PascheWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Wei ZhangWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.
Guangxu JinWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China.ORCID 0000-0001-9451-4886

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Th9 cells as a promising effector T-cell subset for cancer therapyR00CA190910 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LU, YONG · 2017 to 2019
$747k
Th9 cells as a promising effector T-cell subset for cancer therapyK99CA190910 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LU, YONG · 2015 to 2016
$185k
NCATS NIH HHS UL1 TR001420NCI NIH HHS K99 CA190910NCI NIH HHS P30 CA012197NCI NIH HHS R00 CA190910
6 · The paper itself

Abstract

There is a lack of robust generalizable predictive biomarkers of response to immune checkpoint blockade in multiple types of cancer. We develop hDirect-MAP, an algorithm that maps T cells into a shared high-dimensional (HD) expression space of diverse T cell functional signatures in which cells group by the common T cell phenotypes rather than dimensional reduced features or a distorted view of these features. Using projection-free single-cell modeling, hDirect-MAP first removed a large group of cells that did not contribute to response and then clearly distinguished T cells into response-specific subpopulations that were defined by critical T cell functional markers of strong differential expression patterns. We found that these grouped cells cannot be distinguished by dimensional-reduction algorithms but are blended by diluted expression patterns. Moreover, these identified response-specific T cell subpopulations enabled a generalizable prediction by their HD metrics. Tested using five single-cell RNA-seq or mass cytometry datasets from basal cell carcinoma, squamous cell carcinoma and melanoma, hDirect-MAP demonstrated common response-specific T cell phenotypes that defined a generalizable and accurate predictive biomarker.

Indexed as

ImmunotherapyMelanomaBiomarkersHumansT-LymphocytesBiomarkersPareto optimizationprojection-free single-cell modelingresponse to immune checkpoint blockadesingle-cell mass cytometry (CyTOF)single-cell RNA sequencing (scRNA-seq)

Identifiers

PMID35037026
PMCPMC8921624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.